Tempest Therapeutics (NASDAQ:TPST) Posts Earnings Results

Tempest Therapeutics (NASDAQ:TPST) issued its quarterly earnings data on Thursday. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.07), Zacks reports. The firm had revenue of $0.49 million for the quarter.

Tempest Therapeutics Price Performance

Shares of NASDAQ TPST traded down $0.07 during midday trading on Friday, reaching $0.77. The company’s stock had a trading volume of 513,994 shares, compared to its average volume of 2,094,879. The stock has a market capitalization of $33.70 million, a P/E ratio of -0.50 and a beta of -1.83. The firm has a 50 day moving average price of $0.87 and a 200-day moving average price of $0.98. Tempest Therapeutics has a 12-month low of $0.70 and a 12-month high of $6.00.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Scotiabank cut their target price on Tempest Therapeutics from $13.00 to $7.00 and set a “sector outperform” rating on the stock in a research report on Friday. HC Wainwright dropped their price objective on Tempest Therapeutics from $47.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.